Lixivaptan FDA Approval Status
FDA Approved: No
Generic name: lixivaptan
Company: Chiesi USA, Inc.
Treatment for: Hyponatremia
Lixivaptan is an investigational selective vasopressin 2 receptor antagonist for the treatment of symptomatic hypervolemic and euvolemic hyponatremia.
In November 2012, Cornerstone Therapeutics Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for lixivaptan had not been approved.
Development timeline for lixivaptan
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
